Clinical trials: Atopic Eczema
Dermatitis, Atopic
Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)
Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study
- Trial name
- NCT07582237
- Where
- South Korea
- Volunteers
- 262 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
Exploratory Study on Lactibiane Topic AD on Skin Flora and Barrier Reinforcement in Mild to Moderate Atopic Dermatitis
This exploratory study aims to evaluate the impact of a cosmetic product (Lactibiane Topic AD) vs placebo on skin flora and skin reinforcement barrier in mild to moderate atopic dermatitis using biometrological, biological and…
- Trial name
- NCT04728269
- Testing
- Lactibiane Topic AD
- Where
- France
- Volunteers
- 10 people
- Sponsor
- PiLeJe
Atopic Dermatitis
A Phase I Clinical Trial to Evaluate CU-10101 Unguent
The study was conducted in two parts:Part 1 and Part 2.Part 1 is a single-site,randomized,double-blind,vehicle-controlled single and multiple administration,dose-escalation study in healthy Chinese participants.There are four…
- Trial name
- NCT06744569
- Testing
- CU-10101
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Moderate-to-severe Atopic Dermatitis
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
- Trial name
- NCT05186922
- Testing
- CM326
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Keymed Biosciences Co.Ltd
Dermatitis, Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- JADE Compare (NCT03720470)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab
- Where
- 216 sites in United States, Australia and 16 more
- Volunteers
- 838 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients
- Trial name
- NCT04369846
- Testing
- GM-XANTHO onitment
- Where
- 4 sites in Taiwan
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Xantho Biotechnology Co., LTD
Eczema, Hand Eczema
A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema
The primary objective of this protocol is to acquire pilot data for a larger study to test the following hypothesis: Treatment of the hands of patients with chronic hand dermatitis/atopic dermatitis with CLn BodyWash, a novel gel…
- Conditions
- Eczema, Hand Eczema, Atopic Dermatitis
- Trial name
- NCT01826630
- Testing
- CLn BodyWash, Cetaphil Daily Facial Cleanser
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shari L Hand
Atopic Dermatitis
A Study of E6005 in Japanese Patients With Atopic Dermatitis
The safety and pharmacokinetics of topical application with E6005 ointment compared to vehicle will be evaluated in Japanese male patients with atopic dermatitis.
- Trial name
- NCT01179880
- Testing
- E6005
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Atopic Dermatitis, Atopic Dermatitis, Unspecified
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Trial name
- NCT05732454
- Testing
- etrasimod
- Where
- 74 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- Pfizer
Moderate to Severe Atopic Dermatitis
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT03568162
- Testing
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3
- Where
- 83 sites in United States, Canada and 3 more
- Volunteers
- 462 people
- Sponsor
- Ichnos Sciences SA
Moderate/Severe Atopic Dermatitis
Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis
To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.
- Trial name
- NCT01745159
- Testing
- tacrolimus
- Where
- 4 sites in China
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma China, Inc.
Atopic Dermatitis
Evaluation of the Efficacy of TOPIALYSE Baume Protect+ on Atopic Dermatis
The purpose of this study is to evaluate the efficacy and tolerability of a SVR care product. As we know, atopic dermatitis is a vicious circle that must be broken, but certain aggravating factors are added to this circle.
- Trial name
- TOPIAbis (NCT06108570)
- Testing
- Cosmetic Product TOPIALYSE Baume Protect+
- Where
- 3 sites in Belgium
- Volunteers
- 60 people
- Sponsor
- SVR Group
Atopic Dermatitis
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Heads Up (NCT03738397)
- Testing
- Upadacitinib, Dupilumab
- Where
- 159 sites in United States, Australia and 21 more
- Volunteers
- 673 people
- Sponsor
- AbbVie
Healthy
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see: how the body processes the study medicine and if food affects the amount of study…
- Trial name
- NCT06686797
- Testing
- PF-08049820
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured…
- Trial name
- ADTrust (NCT06815380)
- Testing
- No Intervention
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis (AD)
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
This is a multinational (China and Korea), multicenter, randomized, double-blind, vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1% OPA-15406 ointment to the vehicle in adult AD subjects.
- Trial name
- NCT05667623
- Testing
- 1% OPA-15406 Ointment, 0% OPA-15406 Vehicle
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Otsuka Beijing Research Institute
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
- Trial name
- ECZTRA 2 (NCT03160885)
- Testing
- Tralokinumab
- Where
- 115 sites in United States, Australia and 7 more
- Volunteers
- 794 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis
The primary objective of this trial is to investigate the safety and tolerability of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT03514511
- Testing
- LEO 138559
- Where
- 3 sites in United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Atopic Dermatitis, Atopic Dermatitis Eczema
The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (14 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Trial name
- NCT05719649
- Testing
- Lactic acid bacteria NTU 101
- Volunteers
- 72 people
- Sponsor
- SunWay Biotech Co., LTD.